ArticleBMC pediatrics2026
Efficacy of phloroglucinol in pediatric acute intussusception and development of a predictive model for treatment failure: a retrospective cohort study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute intussusception is a common abdominal emergency in children. Although air enema reduction is an established effective treatment, the use of intravenous phloroglucinol alone for this condition has rarely been reported. This study aimed to evaluate the efficacy of phloroglucinol compared with air enema for pediatric acute intussusception and to develop and validate a predictive model for phloroglucinol treatment failure, aiding clinicians in early identification of high-risk children for timely management adjustment and prevention of severe complications.
methodsWe retrospectively analyzed clinical data from 1149 children with acute intussusception admitted to our hospital between January 2014 and December 2023. Baseline characteristics, clinical presentations, and ultrasound findings were collected. We used chi-square test to compare treatment outcomes between the phloroglucinol group (n = 757) and the air enema group (n = 392). Children in the phloroglucinol group were randomly divided into training and validation sets at a 7:3 ratio. Independent risk factors for phloroglucinol treatment failure were identified using univariate and multivariate logistic regression analyses, and a predictive model was constructed accordingly. Model performance was assessed using receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).
results(1) No statistically significant difference was observed in treatment success rates between the phloroglucinol and air enema groups (93.7% vs. 95.4%, P = 0.227). (2) Multivariate logistic regression analysis identified duration of symptoms, vomiting, and intussusception depth as independent risk factors for phloroglucinol treatment failure (all P < 0.05). A nomogram incorporating these factors achieved an area under the ROC curve (AUC) of 0.96 (95%CI: 0.94-0.99) in the training set and 0.93 (95%CI: 0.81-1.00) in the validation set. Calibration curves demonstrated excellent agreement between predicted probabilities and observed outcomes. DCA indicated a significant clinical net benefit of the model.
conclusionPhloroglucinol appears to be an effective treatment option for pediatric acute intussusception. The developed nomogram, based on duration of symptoms, vomiting, and intussusception depth, exhibits robust predictive performance and may serve as a convenient and reliable tool for the early identification of children at high risk for phloroglucinol treatment failure, facilitating timely clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.